Ofatumumab, Novartis’s fully human anti-CD20 monoclonal antibody, demonstrated a reduction in the risk of 3- and 6-month confirmed disability progression compared to teriflunomide in relapsing multiple sclerosis.
By: Matt Hoffman
Published: April 25, 2020
Xavier Montalban, MD, PhDNew comparative data on ofatumumab, Novartis’ first fully human anti-CD20 monoclonal antibody with a monthly low-dose (20 mg) regimen, suggest that the therapy is superior in efficacy compared to teriflunomide (Aubagio; Sanofi) in treating patients with relapsing multiple sclerosis (MS).1The data, which were accepted for presentation at the American Academy of Neurology (AAN) 2020 Annual Meeting, used pooled analysis from the phase 3 ASCLEPIOS I and II trials and suggest that ofatumumab significantly reduced the risk of 3- and 6-month confirmed disability progression (CDP) compared to teriflunomide, save for in a single subgroup of patients, Subset C.
This article is posted and shared by: #MSViewsandNews
::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews